Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Keystone Symposium on Growing to Extremes: Cell Biology and Pathology of Axons
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Gilenya prescribing information
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Molecular targets of FTY720 (fingolimod).
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial.
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.
Vitamin A and systemic inflammation as protective factors in multiple sclerosis.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Activities of daily living: evaluation and treatment in persons with multiple sclerosis.
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.

Pages